Valuation: Gilead Sciences, Inc.

Market Cap 161B 141B 131B 120B 226B 15,461B 230B 1,557B 608B 7,601B 603B 590B 26,281B P/E 2026 *
-46.6x
P/E 2027 * 16.4x
Enterprise Value 170B 149B 139B 128B 240B 16,385B 243B 1,650B 645B 8,055B 639B 625B 27,852B EV / Sales 2026 *
5.59x
EV / Sales 2027 * 4.97x
Free-Float
99.88%
Yield 2026 *
2.55%
Yield 2027 * 2.64%
1 day+2.49%
1 week-1.03%
Current month+4.35%
1 month+4.36%
3 months+3.20%
6 months-6.48%
Current year+7.41%
1 week 127.61
Extreme 127.61
132.86
1 month 124.19
Extreme 124.19
140.61
Current year 116.88
Extreme 116.88
157.29
1 year 108.46
Extreme 108.4601
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 61 2019-02-28
Director of Finance/CFO 56 2019-10-31
Compliance Officer - 2025-12-17
Director TitleAgeSince
Director/Board Member 58 2016-08-18
Director/Board Member 73 2017-12-31
Director/Board Member 72 2018-05-08
Date Insider Type Main position Quantity % Market Cap.
7/15/26 Sell

Chief Financial Officer

-3,000 0.0002%
7/15/26 Sell

Executive/Senior Manager

-3,000 0.0002%
7/1/26 Sell

Chief Executive Officer

-15,000 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
+2.45%-1.03%+16.64%+72.32% 161B
+0.60%+4.93%+48.92%+164.50% 1,067B
+1.55%+7.31%+60.64%+53.73% 635B
+0.79%+2.96%+38.38%+75.26% 458B
+1.66%+9.13%+38.91%+32.87% 347B
+1.77%+4.91%+38.35%+42.30% 295B
+2.05%+4.73%+20.17%+21.18% 262B
+1.89%-0.82%-27.90%-38.88% 216B
+1.55%+4.59%+26.42%+61.36% 203B
+1.04%-0.02%+1.79%-31.64% 140B
Average +1.55%+0.99%+26.23%+45.30% 378.34B
Weighted average by Cap. +1.30%+1.80%+37.17%+75.26%

Financials

2026 *2027 *
Net sales 30.42B 26.72B 24.85B 22.8B 42.85B 2,930B 43.51B 295B 115B 1,440B 114B 112B 4,980B 32.3B 28.37B 26.38B 24.21B 45.48B 3,110B 46.18B 313B 122B 1,529B 121B 119B 5,287B
Net income -3.39B -2.98B -2.77B -2.54B -4.78B -327B -4.85B -32.89B -12.85B -161B -12.73B -12.45B -555B 9.78B 8.59B 7.99B 7.33B 13.77B 942B 13.98B 94.85B 37.06B 463B 36.71B 35.92B 1,601B
Net Debt 9.6B 8.43B 7.84B 7.19B 13.52B 924B 13.72B 93.09B 36.37B 454B 36.03B 35.25B 1,571B -
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
26-07-27 $132.33 +2.34% 1,314,436
26-07-24 $129.31 -1.18% 5,529,741
26-07-23 $130.86 +0.40% 6,299,287
26-07-22 $130.34 +0.05% 4,757,764
26-07-21 $130.28 -2.20% 8,371,109
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
129.31USD
Average target price
157.52USD
Spread / Average Target
+21.81%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GILD Stock